Clinical trial

COMPARISON OF DEXMEDETOMIDINE AND REMIFENTANIL FOR POSTOPERATIVE PAIN IN TRANSPHENOIDAL Pituitary SURGERY

Name

KocaeliUI

Description

In patients with pituitary adenoma scheduled for endoscopic transsphenoidal pituitary surgery, it was aimed to compare the efficacy of postoperative pain relief of a selective α-2 agonist "Dexmedetomidine" and the rapid and short-acting opioid "Remifentanil" using the "Numerical Rating Scale" (NRS) administered alongside propofol in perioperative maintenance anesthesia. .

Trial arms

Trial start

2021-11-17

Estimated PCD

2022-12-14

Trial end

2023-02-22

Status

Completed

Treatment

Dexmedetomidine

Efficacy of dexmedetomidine on postoperative pain in patients undergoing transsphenoidal pituitary surgery

Arms:

GROUP USING DEXMEDETOMIDINE

Remifentanyl

Efficacy of remifentanyl on postoperative pain in patients undergoing transsphenoidal pituitary surgery

Arms:

GROUP USING REMIFENTANYL

Size

Primary endpoint

postoperative pain scale

at post anesthesia care unit (T1)

postoperative pain scale

2 hours after surgery (T2)

postoperative pain scale

8 hours after surgery (T3)

postoperative pain scale

24 hours after surgery (T4)

Eligibility criteria

Inclusion Criteria: * 18-65 years old * ASA-1 and ASA-2 patients Exclusion Criteria: * Patients in need of postoperative intensive care

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '1 Day', 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 84, 'type': 'ACTUAL'}}

Updated at

2023-03-16

1 organization

2 products

1 indication

Organization

Product

Indication

Product